Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MS Morgan Stanley	$144.50 +1.1%	$129.57	$90.94 ▼ $144.56	$231.25B	1.3	6.69 million shs	3.97 million shs
PTGX Protagonist Therapeutics	$51.20 +1.0%	$49.40	$32.50 ▼ $60.60	$3.16B	2.26	843,939 shs	339,485 shs
UNH UnitedHealth Group	$308.69 +0.4%	$324.99	$248.88 ▼ $630.73	$279.90B	0.45	7.56 million shs	6.16 million shs
WFC Wells Fargo & Company	$83.32 +1.2%	$75.34	$50.15 ▼ $83.95	$272.05B	1.16	17.38 million shs	11.24 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MS Morgan Stanley	0.00%	+2.74%	+10.70%	+44.86%	+44.33%
PTGX Protagonist Therapeutics	0.00%	-8.06%	-4.87%	+15.21%	+48.41%
UNH UnitedHealth Group	0.00%	-0.05%	+4.42%	-41.20%	-36.99%
WFC Wells Fargo & Company	0.00%	+4.91%	+11.27%	+36.77%	+37.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MS Morgan Stanley	4.7005 of 5 stars	2.2	3.0	4.2	2.4	2.7	2.5	2.5
PTGX Protagonist Therapeutics	2.1068 of 5 stars	3.5	1.0	0.0	0.0	2.5	2.5	0.0
UNH UnitedHealth Group	4.9977 of 5 stars	4.3	3.0	4.2	4.0	2.8	3.3	2.5
WFC Wells Fargo & Company	4.7815 of 5 stars	2.4	4.0	2.5	2.5	3.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MS Morgan Stanley	2.41	Hold	$133.62	-7.53% Downside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	29.10% Upside
UNH UnitedHealth Group	2.60	Moderate Buy	$415.57	34.62% Upside
WFC Wells Fargo & Company	2.75	Moderate Buy	$78.33	-5.99% Downside

Current Analyst Ratings Breakdown

Latest UNH, PTGX, WFC, and MS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	WFC Wells Fargo & Company	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$78.00 ➝ $85.00
6/25/2025	UNH UnitedHealth Group	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$400.00 ➝ $385.00
6/20/2025	UNH UnitedHealth Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$405.00 ➝ $418.00
6/18/2025	WFC Wells Fargo & Company	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
6/18/2025	MS Morgan Stanley	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$125.00 ➝ $130.00
6/18/2025	WFC Wells Fargo & Company	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy ➝ Strong-Buy	$78.00 ➝ $84.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/11/2025	UNH UnitedHealth Group	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2025	UNH UnitedHealth Group	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$312.00
6/10/2025	MS Morgan Stanley	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$121.00 ➝ $136.00
6/10/2025	WFC Wells Fargo & Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$76.00 ➝ $86.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MS Morgan Stanley	$107.29B	2.16	$11.54 per share	12.52	$59.39 per share	2.43
PTGX Protagonist Therapeutics	$434.43M	7.30	$4.53 per share	11.30	$11.33 per share	4.52
UNH UnitedHealth Group	$400.28B	0.70	$32.39 per share	9.53	$106.78 per share	2.89
WFC Wells Fargo & Company	$125.40B	2.16	$8.32 per share	10.01	$48.79 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MS Morgan Stanley	$13.39B	$8.52	16.96	15.32	1.32	12.98%	14.98%	1.15%	7/16/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	68.27	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$23.88	12.93	9.29	1.48	5.39%	26.29%	8.67%	7/15/2025 (Estimated)
WFC Wells Fargo & Company	$19.72B	$5.57	14.96	12.13	1.40	16.19%	12.15%	1.03%	7/15/2025 (Estimated)

Latest UNH, PTGX, WFC, and MS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	UNH UnitedHealth Group	$5.16	N/A	N/A	N/A	$111.75 billion	N/A
7/16/2025	Q2 2025	MS Morgan Stanley	$2.01	N/A	N/A	N/A	$16.15 billion	N/A
7/15/2025	Q2 2025	WFC Wells Fargo & Company	$1.41	N/A	N/A	N/A	$20.83 billion	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
4/17/2025	Q1 2025	UNH UnitedHealth Group	$7.29	$7.20	-$0.09	$6.85	$111.56 billion	$109.58 billion
4/11/2025	Q1 2025	MS Morgan Stanley	$2.21	$2.60	+$0.39	$2.60	$16.81 billion	$17.74 billion
4/11/2025	Q1 2025	WFC Wells Fargo & Company	$1.23	$1.39	+$0.16	$1.39	$20.82 billion	$20.15 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MS Morgan Stanley	$3.70	2.56%	N/A	43.43%	12 Years
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
UNH UnitedHealth Group	$8.84	2.86%	N/A	37.02%	15 Years
WFC Wells Fargo & Company	$1.60	1.92%	N/A	28.73%	4 Years

Latest UNH, PTGX, WFC, and MS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/5/2025	UNH UnitedHealth Group	quarterly	$2.21	3%	6/16/2025	6/16/2025	6/24/2025
4/29/2025	WFC Wells Fargo & Company	quarterly	$0.40	2.28%	5/9/2025	5/9/2025	6/1/2025
4/11/2025	MS Morgan Stanley	quarterly	$0.9250	3.48%	4/30/2025	4/30/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MS Morgan Stanley	3.11	0.78	0.78
PTGX Protagonist Therapeutics	N/A	17.25	17.26
UNH UnitedHealth Group	0.71	0.85	0.85
WFC Wells Fargo & Company	1.06	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MS Morgan Stanley	84.19%
PTGX Protagonist Therapeutics	98.63%
UNH UnitedHealth Group	87.86%
WFC Wells Fargo & Company	75.90%

Insider Ownership

Company	Insider Ownership
MS Morgan Stanley	0.19%
PTGX Protagonist Therapeutics	4.90%
UNH UnitedHealth Group	0.28%
WFC Wells Fargo & Company	0.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MS Morgan Stanley	80,000	1.60 billion	1.60 billion	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
UNH UnitedHealth Group	400,000	907.14 million	904.60 million	Optionable
WFC Wells Fargo & Company	217,000	3.25 billion	3.25 billion	Optionable

UNH, PTGX, WFC, and MS Headlines

Recent News About These Companies

The world could get carved up into these 3 blocs as Trump tariffs accelerate deglobalization

July 5 at 4:50 PM | fortune.com

Jim Cramer Says He’s “Very Happy” With Wells Fargo

July 5 at 12:48 PM | finance.yahoo.com

Jim Cramer Says He’s “Very Happy” With Wells Fargo

July 5 at 11:43 AM | insidermonkey.com

Wells Fargo & Company (WFC) Trades At 14 Times Earnings, Says Jim Cramer - Yahoo Finance

July 5 at 11:37 AM | finance.yahoo.com

Jim Cramer Says He’s “Very Happy” With Wells Fargo

July 5 at 11:37 AM | msn.com

Braun Stacey Associates Inc. Raises Stake in Wells Fargo & Company (NYSE:WFC)

July 5 at 8:40 AM | marketbeat.com

Wells Fargo & Company (NYSE:WFC) Shares Sold by Bank of New York Mellon Corp

July 5 at 8:32 AM | marketbeat.com

Generali Investments CEE investicni spolecnost a.s. Takes Position in Wells Fargo & Company (NYSE:WFC)

July 5 at 8:10 AM | marketbeat.com

GF Fund Management CO. LTD. Buys 12,944 Shares of Wells Fargo & Company (NYSE:WFC)

July 5 at 6:27 AM | marketbeat.com

Thomson Reuters: Navigating Competitive Shifts in the Legal Tech Landscape with a Hold Rating

July 5 at 4:18 AM | tipranks.com

Wells Fargo & Company (NYSE:WFC) Price Target Raised to $85.00

July 5 at 2:33 AM | americanbankingnews.com

What To Expect From Wells Fargo Q2 Report After Shares Reach All-Time Highs

July 4 at 3:48 PM | seekingalpha.com

Wells Fargo & Company (NYSE:WFC) Trading Up 1.2% - What's Next?

July 4 at 11:42 AM | marketbeat.com

IFM Investors Pty Ltd Has $50.57 Million Stock Position in Wells Fargo & Company (NYSE:WFC)

July 4 at 8:02 AM | marketbeat.com

Wells Fargo details latest bank branch closings in the Charlotte region and NC

July 4 at 7:22 AM | msn.com

Jim Cramer Highlights that Wells Fargo is “Owned and Beloved” by the Charitable Trust

July 4 at 7:22 AM | msn.com

Wells Fargo & Company (NYSE:WFC) Shares Purchased by Calamos Wealth Management LLC

July 4 at 7:18 AM | marketbeat.com

Wells Fargo & Company (NYSE:WFC) Shares Purchased by Cohen Investment Advisors LLC

July 4 at 7:03 AM | marketbeat.com

Strategic Financial Concepts LLC Sells 28,036 Shares of Wells Fargo & Company (NYSE:WFC)

July 4 at 5:25 AM | marketbeat.com

Wells Fargo & Company (NYSE:WFC) Shares Up 1% After Analyst Upgrade

July 4 at 2:29 AM | americanbankingnews.com

Wells Fargo's Asset Cap Is Lifted – What Happens Next?

July 4 at 2:22 AM | usnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
By Gabriel Osorio-Mazilli | July 3, 2025
View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
By Jeffrey Neal Johnson | June 13, 2025
View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
3 Oversold Stocks Flashing Bullish Reversal Signals
By Sam Quirke | June 7, 2025
View 3 Oversold Stocks Flashing Bullish Reversal Signals
Congress’s May Stock Trades: What They Know That You Don’t
By Thomas Hughes | June 20, 2025
View Congress’s May Stock Trades: What They Know That You Don’t

UNH, PTGX, WFC, and MS Company Descriptions

Morgan Stanley NYSE:MS

$144.50 +1.64 (+1.15%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$144.50 0.00 (0.00%)

As of 07/3/2025 04:55 PM Eastern

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.

Protagonist Therapeutics NASDAQ:PTGX

$51.20 +0.51 (+1.01%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$51.18 -0.03 (-0.05%)

As of 07/3/2025 04:20 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

UnitedHealth Group NYSE:UNH

$308.69 +1.13 (+0.37%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$308.61 -0.08 (-0.03%)

As of 07/3/2025 05:00 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Wells Fargo & Company NYSE:WFC

$83.32 +0.96 (+1.16%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$83.48 +0.17 (+0.20%)

As of 07/3/2025 04:59 PM Eastern

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time